Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,957 Cr
verified against source
Revenue YoY
4%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Cipla reported Q1 FY26 revenue of INR 6,957 crore (+4% YoY) with EBITDA margin of 25.6% (flat YoY) and PAT of INR 1,298 crore (+10.2% YoY). India business crossed INR 3,000 crore for the first time in a Q1, growing 6% YoY, but branded prescription growth was muted due to slow respiratory/acute market (4-5% growth) and sales force realignment. US revenue was $226 million, impacted by price erosion in a large product, but new launches (NanoPaclitaxel, Nilotinib) and Lanreotide recovery provide cushion. Management maintained FY26 EBITDA margin guidance of 23.5%-24.5%. Key risks include Revlimid revenue phasing uncertainty and slower India branded growth recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D investments.
- CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.
- COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.
- Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
Risks flagged
- Management could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.
- India branded business grew only ~3% (ex-consumer), impacted by slow respiratory/acute market and sales force realignment; recovery may take longer.
- Indore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
- Management acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share.
Key quotes
- What makes this performance commendable is that it builds on a strong prior year-on-year quarter where we achieved the highest-ever US generic revenue.
- We are adjusting to the older, larger products substituting themselves due to price erosion. What is balancing these in is the new launches that are helping us sustain momentum.
- We are a little early for us to give guidance for next year. Closer to the year-end, when we're in position to give that guidance, seeing how the market shapes up after that is when we'll be in better position to do that.
Research modules